Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study
American Journal of Hypertension · 2023
DOI: 10.1093/ajh/hpad066 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, 2023. Verfasst von George L Bakris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Hypertension, Renal Insufficiency, Chronic, Blood Pressure, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KBP BioSciences.
Abstract (Originalsprache)
BACKGROUND Ocedurenone (KBP-5074), a nonsteroidal mineralocorticoid receptor antagonist, is documented to lower blood pressure in patients with stage 3b/4 chronic kidney disease (CKD) with uncontrolled or resistant hypertension (BLOCK-CKD study). However, the efficacy and safety of Ocedurenone in subgroups such as Hispanic patients or those with stage 4 CKD, diabetes, or very high albuminuria have not been reported. METHODS A total of 162 patients were enrolled in the BLOCK-CKD study. The primary endpoint of these analyses was change in systolic blood pressure (SBP) from baseline to day 84. Prespecified subgroup analysis of SBP focused on demographic (e.g., ethnicity, age) and medical (e.g., CKD stage, diabetes, albuminuria, baseline estimated glomerular filtration rate [eGFR]). The safety analysis focused on changes in serum potassium levels from baseline. RESULTS SBP reductions were consistent across subgroups compared with the overall study cohort. Placebo-adjusted SBP reductions were observed in Hispanic patients (−8.1 and −9.9 mm Hg for 0.25 and 0.5 mg, respectively, total n = 35) and patients with CKD stage 4 (−9.3 and −10.4 mm Hg for 0.25 and 0.5 mg, respectively, total n = 64), diabetes (−6.9 and −11.6 mm Hg for 0.25 and 0.5 mg, respectively, total n = 51), and very high albuminuria (−13.1 and −12.3 mm Hg for 0.25 and 0.5 mg, respectively, total n = 85). Changes in serum potassium were similar across all patient subgroups regardless of baseline eGFR, diabetes status, or degree of proteinuria. No cases of hyperkalemia required intervention or resulted in study discontinuation. CONCLUSIONS Ocedurenone consistently reduced in SBP in all patient subgroups. Moreover, while small elevations in serum potassium occurred, they were not associated with Ocedurenone or study discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, Illinois, USA.
- Chief Development Officer, KBP BioSciences USA Inc., Princeton, New Jersey, USA.
- Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
ORCID-Profile: George L Bakris
Förderung
- KBP BioSciences
Zitieren
APA
Bakris, G. L., Yang, Y. F., McCabe, J. M., Liu, J. R., Tan, X. J., Benn, V. J., & Pitt, B. (2023). Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpad066
Vancouver
Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, et al. Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. American Journal of Hypertension. 2023. doi:10.1093/ajh/hpad066
BibTeX
@article{Bakris2023,
author = {Bakris, George L and Yang, Y Fred and McCabe, James M and Liu, Jin Rong and Tan, Xiaojuan J and Benn, Vincent J and Pitt, Bertram},
title = {Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study},
journal = {American Journal of Hypertension},
year = {2023},
doi = {10.1093/ajh/hpad066}
}
EUVIMED